Lincoln Pharmaceuticals Share Price

NSE
LINCOLN •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Lincoln Pharmaceuticals Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
42.28% Fall from 52W High
-28.6
Dividend yield 1yr %
Below industry Median
0.3

Lincoln Pharmaceuticals Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Lincoln Pharmaceuticals Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
146.55 Cr
161.21 Cr
147.28 Cr
142.49 Cr
146.45 Cr

Lincoln Pharmaceuticals Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
614.97 Cr
532.78 Cr
482.12 Cr
429.85 Cr
397.53 Cr

Lincoln Pharmaceuticals Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
20.77 Cr
26.33 Cr
23.67 Cr
18.6 Cr
28.04 Cr

Lincoln Pharmaceuticals Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
93.3 Cr
72.9 Cr
69.36 Cr
62.25 Cr
51.47 Cr
Lincoln Pharmaceuticals Result Highlights
  • Lincoln Pharmaceuticals Ltd reported a 9.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 1.2%.

  • Its expenses for the quarter were down by 7.0% QoQ and up 5.9% YoY.

  • The net profit decreased 21.1% QoQ and decreased 25.9% YoY.

  • The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 10.4 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lincoln Pharmaceuticals shareholding Pattern

Promoter
49.8%
Foreign Institutions
5%
Public
45.2%
Promoter
49.8%
Foreign Institutions
5.2%
Public
45.1%
Promoter
49.8%
Foreign Institutions
5.2%
Public
45%
Promoter
49.8%
Foreign Institutions
4%
Public
46.2%
Promoter
49.5%
Foreign Institutions
3.9%
Domestic Institutions
0.1%
Public
46.5%
Promoter
49.8%
Foreign Institutions
3.2%
Domestic Institutions
0.1%
Public
46.9%

Lincoln Pharmaceuticals Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
9
Bearish Moving Averages
7
5Day EMA
562.40
10Day EMA
558.30
12Day EMA
557.50
20Day EMA
558.10
26Day EMA
562.30
50Day EMA
591.50
100Day EMA
634.50
200Day EMA
650.80
5Day SMA
559.10
10Day SMA
557.20
20Day SMA
555.10
30Day SMA
550.50
50Day SMA
582.90
100Day SMA
686.40
150Day SMA
685.40
200Day SMA
682.20
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
28280 Rs
53290 Rs
Week Rs
20004 Rs
38521 Rs
Month Rs
34205 Rs
64645 Rs
Resistance & Support
569.42
Pivot
Resistance
First Resistance
578.33
Second Resistance
591.32
Third Resistance
600.23
Support
First Support
556.43
Second support
547.52
Third Support
534.53
Relative Strength Index
50.78
Money Flow Index
59.46
MACD
-4.73
MACD Signal
-9.90
Average True Range
24.99
Average Directional Index
17.44
Rate of Change (21)
7.29
Rate of Change (125)
-15.80

Lincoln Pharmaceuticals Company background

Founded in: 1995
Managing director: Mahendra G Patel
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes antiinfective, respiratory system, gynecology, cardio CNS, antidiabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake inhouse testing of its products for better quality control and RD. It came out with a public issue in Feb.96 to partfinance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 202122, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022.
Read More

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹565.35 in NSE and ₹565.4 in BSE as on 16/4/2025.

Lincoln Pharmaceuticals share price in the past 1-year return was -2.66. The Lincoln Pharmaceuticals share hit a 1-year low of Rs. 499 and a 1-year high of Rs. 979.5.

The market cap of Lincoln Pharmaceuticals is Rs. 1132.38 Cr. as of 16/4/2025.

The PE ratios of Lincoln Pharmaceuticals is 12.67 as of 16/4/2025.

The PB ratios of Lincoln Pharmaceuticals is 1.77 as of 16/4/2025

You can easily buy Lincoln Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Lincoln Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -